Abstract 188P
Background
A thorough investigation of the tumor cells and immune microenvironment within the lead-edge area is essential for understanding the mechanisms behind the progression of ICC and devising a targeted therapy in the hope of providing clinical benefits for patients.
Methods
Here, we conducted an analysis based on single-cell RNA sequencing (scRNA-seq) and spatial transcriptome (ST) on samples from the tumor core, paired non-tumorous tissue, and the leading-edge area obtained from 9 ICC patients to delineate the properties of cancer cells, immune microenvironment, and the intricate intercellular interactions within. The analysis results were further validated using H&E staining, multiple immunofluorescence staining (IHC), and a large transcriptome dataset.
Results
Tumor cells at the leading-edge area exhibit a heightened capacity for proliferation compared to those in the tumor core, often found in close proximity to the stroma, including endothelial cells and POSTN+ FAP+ fibroblasts. Within this region, CD8+ T cells are characterized by a naive phenotype, displaying low levels of cytotoxicity and exhaustion, a condition that may be linked to the impaired antigen-presenting capabilities of antigen-presenting cells (APCs). MAIT cells, which are the predominant CD8+ T cell subset infiltrating the leading-edge area of ICC, have been observed to recruit SPP1+ macrophages and are co-localized with POSTN+ cancer-associated fibroblasts (CAFs) in the stromal compartment. The presence of SPP1+ macrophages could potentially foster tumor progression through the activation of CD44 in tumor cells, as well as by their proangiogenic effects.
Conclusions
Utilizing scRNA-seq and spatial transcriptome technologies, our research delineates the distinct characteristics of ICC tumor cells within the leading-edge area, revealing how they interact with and influence the surrounding stroma to sculpt the immune microenvironment. These orchestrated interactions within the tumor milieu offer valuable insights and pinpoint potential therapeutic targets for intervention.
Legal entity responsible for the study
Peking University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
165P - TIGIT inhibition in non-small cell lung cancer: Meta-analysis of clinical efficacy and biomarker correlation
Presenter: Hashim Talib Hashim
Session: Poster Display session
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session